Myasthenia Gravis
Myasthenia gravis (MG) can affect many aspects of daily life, from vision and movement to speaking, swallowing and breathing.1,2 Symptoms can vary considerably between people and may fluctuate from hour to hour or day to day.3 While MG cannot currently be cured, treatment can help manage symptoms, and timely diagnosis, coordinated care and access to specialist support can make an important difference.1,4,5
What is Myasthenia Gravis (MG)?
Myasthenia gravis (MG) is a rare, chronic autoimmune neurological condition – it disrupts communication between nerves and voluntary muscles, causing weakness that typically worsens with activity and improves with rest. Drooping eyelids and double vision are often its most recognised features, but MG can also affect facial expression, speech, chewing, swallowing, breathing, and movement in the neck, arms and legs.1,2
Its unpredictable symptoms can create challenges that extend beyond muscle weakness, affecting everyday activities and quality of life.2,6 Improving outcomes for people living with MG requires timely diagnosis, coordinated care and practical support.5
How common is MG?
Myasthenia gravis is a rare condition that affects an estimated 20,000 people in the UK.7
What are the symptoms of MG?
The first signs of MG are often drooping eyelids and double vision. This is because the muscles controlling eye and eyelid movements are usually the first to be affected.2,8
Regardless of the type of MG, most people experience weakness of the muscles surrounding the eyes at some stage. For those diagnosed with ocular MG, these are the only affected muscles, whereas for those diagnosed with generalised MG, other muscles are also affected.8
Other symptoms of MG depend on the muscle groups involved and may include:1,2,3
- Muscle weakness in arms and legs
- Difficulties holding the head up
- Changes in facial expression
- Difficulty chewing or swallowing
- Impaired speech
- Fatigue
The symptoms of MG are unpredictable and can fluctuate over hours, or even days,3 making each individuals’ experience deeply personal. This can cause a profound impact not only on a person physically, but also on their emotional, social and economic wellbeing.3,9
What causes MG?
Myasthenia gravis is caused by the immune system mistakenly producing antibodies that disrupt communication between nerves and muscles, leading to muscle weakness.1 It is not fully understood why this autoimmune response develops, although the thymus gland, which forms part of the immune system, is closely associated with the condition.1
Can MG be cured?
There is currently no cure for MG, but treatment can help control symptoms, and some people experience periods of remission.1,4,5
What are the unmet needs in MG care?
Unmet needs in MG care include timely diagnosis by healthcare professionals, better coordinated and more consistent care, and improved access to specialist services and appropriate treatments.5,10
What is UCB's work in MG?
As a leader in immune-mediated rare diseases, UCB is committed to the development of new solutions that may help transform the lives of people living with MG, and we are aware of the urgent unmet medical need that persists for more treatment options.
We remain committed to building strong partnerships with the rare conditions’ community, including patient organisations with an interest in MG.
Interested in UCB's approach to rare diseases?
The Aspire4Rare Framework is a global policy guidance framework developed by UCB and a multidisciplinary panel of rare disease experts. It aims to help governments, policymakers, healthcare systems, researchers, and patient organisations strengthen health systems for the estimated 300 million people living with rare diseases worldwide, offering a practical framework, measurable outcomes, and examples of good practice to guide rare disease policy development and implementation.
To learn more about myasthenia gravis, head to Muscular Dystrophy UK or myaware.
References
1. NHS. Myasthenia gravis: Overview. Available at: https://www.nhs.uk/conditions/myasthenia-gravis/ Last accessed: October 2026.
2. NHS. Myasthenia gravis: Symptoms. Available at: https://www.nhs.uk/conditions/myasthenia-gravis/symptoms/ Last accessed: October 2026
3. Jackson K, et al. Understanding the Symptom Burden and Impact of Myasthenia Gravis from the Patient's Perspective: A Qualitative Study. Neurol Ther. 2023 Feb;12(1):107-128. doi: 10.1007/s40120-022-00408-x
4. Myaware. What is myasthenia? Available at: https://www.myaware.org/what-is-myasthenia Last accessed: October 2026
5. NHS. Myasthenia gravis: Treatment. Available at: https://www.nhs.uk/conditions/myasthenia-gravis/treatment/ Last accessed: October 2026
6. McCallion J et al. Systematic review of the patient burden of generalised myasthenia gravis in Europe, the Middle East, and Africa. BMC Neurology. 2024;24:61. doi:10.1186/s12883-024-03553-y.
7. Myaware. GP Information Available at: https://www.myaware.org/gp-information Last accessed: October 2026
8. Gilhus, et al. Myasthenia gravis. Nat Rev Dis Primers 5, 30 (2019). https://doi.org/10.1038/s41572-019-0079-y
9. Marbin D, et al. Mental health in myasthenia gravis patients and its impact on caregiver burden. Sci Rep. 2022 Nov 11;12(1):19275. doi: 10.1038/s41598-022-22078-3
10. Meisel A, et al. Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis. European Journal of Neurology. 2024;31:e16280. doi:10.1111/ene.16280.
Last updated: October 2026
IE-DA-2400182